Enristomig by Inhibrx for Non-Small Cell Lung Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Enristomig overview

Enristomig (INBRX-105, ES-101) is under development for the treatment of solid tumors, adenocarcinoma of the gastroesophageal junction, nasopharyngeal cancer, oropharyngeal cancer, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, urothelial cell carcinoma, small cell lung cancer, esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer. It is administered through the intravenous route. The drug candidate is a tetravalent single domain antibody (sdAb)-based bi-specific monoclonal antibody that acts by targeting tumor necrosis factor receptor superfamily member 9 (4-1BB or CD137) and cells expressing programmed cell death 1 ligand 1 (PD-L1). 

It was also under development for the treatment of Hodgkin and Non-Hodgkin lymphoma.

Inhibrx overview

Inhibrx is a biotechnology company that discovers and develops biologic therapeutics for the treatment of cancer and infectious diseases. It is investigating INBRX-101, a recombinant human AAT-Fc fusion protein candidate for the treatment of AATD (alpha-1 antitrypsin deficiency); INBRX-109, an engineered tetravalent sdAb-based therapeutic candidate to treat cancer by activating DR5 (death receptor 5). The company is also evaluating the INBRX-106 program against advanced or metastatic solid tumors; and INBRX-105 therapeutic candidate targeting patients with programmed death-ligand 1 (PD-L1) expressing tumors. It utilizes its proprietary sdAb (single-domain antibody) platform to develop biotherapeutics that interface with the biology of each target antigen by focusing on immune activation and mediating enhanced signaling. Inhibrx is headquartered in La Jolla, California, the US.

For a complete picture of Enristomig’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.